Published on 6 May 2024 on 3BL CSRwire
Forbes has listed Gilead as one of America’s Best Employers for Diversity. Gilead Sciences, Inc. is a research-based biopharmaceutical ...
Start tracking your investments with Statfolio
Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains,...
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new...
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The...
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in...
On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S....
We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 2...
, opens new tab Trodelvy failed to improve survival for patients with advanced bladder cancer and...
A drug at the center of a $21 billion acquisition by Gilead Sciences Inc. four years ago failed a...
On Thursday, Gilead Sciences Inc GILD announced topline results from the confirmatory Phase 3 TRO...
Gilead Sciences, Inc. GILD announced the failure of its late-stage confirmatory TROPiCS-04 study ...